- Home
- NPCE vs BME Comparison
NPCE vs BME Comparison
Compare NPCE & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPCE | BME |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.3M | 547.5M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NPCE | BME |
|---|---|---|
| Price | $14.75 | $42.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.33 | N/A |
| AVG Volume (30 Days) | ★ 143.6K | 34.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,906,000.00 | N/A |
| Revenue This Year | $25.95 | N/A |
| Revenue Next Year | $0.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.56 | $34.18 |
| 52 Week High | $18.97 | $42.63 |
Technical Indicators
Market Signals| Indicator | NPCE | BME |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 54.45 |
| Support Level | $14.02 | $41.21 |
| Resistance Level | $16.96 | $42.46 |
| Average True Range (ATR) | 0.71 | 0.47 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 25.05 | 55.83 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.